Phase 2
N=236
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
HIV Infections · Schizophrenia · Schizoaffective Disorder · Bipolar Disorder · Depression
Bottom Line
View on ClinicalTrials.gov: NCT00316303 ↗Enrolled (actual)
236
Serious AEs
0.0%
Results posted
May 2013
Primary outcome: Primary: Change in Immunization Status — 73; 4 participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Twinrix (Drug); Enhanced treatment as usual (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Primary completion
- Apr 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Immunization Status |
73; 4 | <0.001 sig |
| PRIMARY Tested for Hepatitis C |
70; 10 | <0.001 sig |
| PRIMARY Tested for Hepatitis B |
69; 14 | <0.001 sig |
| PRIMARY Tested for HIV |
18; 6 | 0.011 sig |
| PRIMARY Referral for Medical Care |
17; 12 | 0.6 |
Summary
This study will determine the effectiveness of the STIRR (Screen, Test, Immunize, Reduce risk, and Refer) intervention in increasing rates of testing, immunization, referral, and treatment for blood-borne diseases, such as hepatitis and HIV, in people with both a mental disorder and a substance abuse disorder.
Eligibility Criteria
Inclusion Criteria
- DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression
- Diagnosis of a substance use disorder
- Enrolled in clinical care at Creative Alternatives or People Encouraging People for at least 3 months
Exclusion Criteria
- Pregnant
Data sourced from ClinicalTrials.gov (NCT00316303). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.